ClinicalTrials.gg
Not yet recruitingNCT07587385Updated May 14, 2026

A Study of HS-10506 in Chinese Patients With Insomnia Disorder

A Phase 3 interventional study of HS-10506 and Placebo in Insomnia Disorder, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
732
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The primary purpose of this phase 3 study is to evaluate the safety and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) and wakefulness after sleep onset (WASO) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder.

Read the detailed description

The study will comprise 4 periods : a Screening Period, a Run-in Period, a Treatment Period during which participants will be treated for 84 nights (3 month) and a minimum 3-day Follow-up Period before an End of Study (EOS) Visit. The total study duration for each participant on this study is 105-113 days.

02

Conditions studied

  • Insomnia Disorder

Keywords

  • Clinical trial
  • insomnia disorder
  • phase 3
03

In context

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.

This study's planned enrollment of 732 is above the median of 68 across 2,355 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. participants must be 18 to 65 years of age (inclusive 18, not inclusive 65);
  2. participants are required to voluntarily sign the form;
  3. (BMI): BMI (weight/height2 [kg/m2]) must be in the range of 18 to 35 kg/m2 (inclusive);
  4. Participants must meet (5th edition) (DSM-5) criteria for insomnia disorder;
  5. Participants must have Insomnia Severity Index (ISI) scores ≥ 15 at screening and run-in period;
  6. Subjective sleep assessment: Participants must have an sSOL≥30 minutes, sWASO≥30 minutes, and sTST \< 6.5 hours for at least three nights every week within one month prior to screening; and sSOL ≥ 30 minutes, sWASO≥30 minutes, and sTST \< 6.5 hours for at least 3 nights from sleep diary in the last 7 consecutive days before V2 visit and V3 visit respectively;
  7. PSG: Participants must demonstrate a 2-night mean LPS ≥ 30 minutes with neither night \< 20 minutes, a 2-night mean WASO ≥ 30 minutes with neither nigh \< 20 minutes, and a 2-night mean TST \< 7 hours.

Exclusion criteria

Exclusion Criteria:

  1. Has history of/current sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;
  2. Has a Apnea-Hypopnea Index (AHI) ≥ 10 times/hour or periodic leg movement with arousal index (PLMAI) ≥ 10 times/hour monitored by PSG at V2 visit;
  3. Has history of/current neurodevelopmental retardation, cognitive impairment, epilepsy, schizophrenia, bipolar disorder, hyperthyroidism, cancer, severe cardio-cerebrovascular diseases or respiratory diseases; or current chronic pain that affects sleep, nocturia resulting in frequent need to get out of bed to use the bathroom during the night; or and/or unstable neurological, psychiatric, respiratory, cardiovascular, digestive, immunologic, urologic, endocrine diseases within the past 3 months prior to screening; or other systemic diseases that are inappropriate for the study;
  4. Has a Hamilton Anxiety Scale (HAM-A) score ≥ 14 or Hamilton Depression Scale (HAM-D-17) score ≥ 18;
  5. Has used any medication that may affect the pharmacokinetics of HS-10506 or GLP-1R-related single/multi-target drugs within the past 2 weeks or 5 half-lives of the medication;
  6. Has used any medication that may affect sleep-wake function, or any other prohibited central nervous system active medications within 1 week or 5 half-lives of the medication;
  7. Has received systemic hypnotherapy, cognitive behavioral therapy (CBT), or other non-pharmacological treatments for insomnia in last 4 weeks or have plans during the study;
  8. Has been working across 3 or more time zones or shift work within 2 weeks prior to screening;
  9. Has taken more than 3 naps per week for > 1 hour each time within the past 2 weeks prior to screening;
  10. Has a risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS), or has a high risk of suicide at the discretion of the investigator;
  11. Has a history of drug dependency or abuse within the past 1 year or showed positive in urine drug test at screening;
  12. Has a history of alcohol abuse within the past 1 year or can't obey the rules of alcohol restriction;
  13. Has a history of smoking ≥ 10 cigars daily within the past 3 months or can't obey the rules of cigar restriction;
  14. Has a history of caffeine consumption ≥ 600 mg per day or can't obey the rules of caffeine restriction;
  15. Previously participated in any clinical trial of HS-10506;
  16. Has any circumstances or conditions, which, in the opinion of the investigator, may affect the participant's full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
732 participants (estimated)

Study arms

  • Experimental
    HS-10506

    Participants will receive HS-10506 tablets, orally, once nightly for 84 consecutive nights

    Drug: HS-10506

  • Placebo comparator
    Placebo

    Participants will receive placebo matched in appearance to HS-10506 tablets, orally, once nightly for 84 consecutive nights

    Drug: Placebo

Interventions

  • HS-10506 tablet

  • DrugPlacebo

    Placebo tablet matched to HS-10506

06

What researchers measure

Primary outcomes

  1. Change from baseline of mean latency to persistent sleep (LPS) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506

    LPS was defined as the time in minutes from lights off to the first epoch of 20 consecutive epochs of non-wakefulness as measured by polysomnography (PSG)

    Time frame: Baseline, Night 27 and Night 28,Night 83 and Night 84

  2. Change from baseline of mean wakefulness after sleep onset (WASO) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506

    WASO was defined as minutes of wake from the onset of persistent sleep until lights on as measured by PSG

    Time frame: Baseline, Night 27 and Night 28, Night 83 and Night 84

Secondary outcomes

  1. Change from baseline of subjective sleep onset latency (sSOL) under the treatment of HS-10506

    sSOL: estimated minutes from the time that the participant attempted to sleep until sleep onset as recorded in sleep diary

    Time frame: Baseline, Week 4, Week 12

  2. Change from baseline in subjective sleep efficiency (sSE) under the treatment of HS-10506

    sSE: the ratio of subjective total sleep time(sTST) to subjective time in bed, sTST: the total sleep time reported by the participant in sleep diary.

    Time frame: Baseline, Week 4, Week 12

  3. Change from baseline in total sleep time (TST) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506

    TST was defined as the total sleep time in minutes, the total sleep time is the total amount of stages 1, 2, 3 non rapid eye-movement (NREM) and rapid-eye-movement (REM) sleep time, as measured by PSG

    Time frame: Baseline, Night 27 and Night 28, Night 83 and Night 84

  4. Change from baseline in sleep efficiency (SE) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506

    SE was defined as percentage (%) of time spent in bed asleep, calculated as total sleep time (TST) divided by interval from lights off until lights on as measured by PSG multiplied by 100

    Time frame: Baseline, Night 27 and Night 28, Night 83 and Night 84

  5. Change from baseline in subjective wake after sleep onset (sWASO) under the treatment of HS-10506

    sWASO: estimated minutes of wake at night from initial sleep onset to the time when the participant stopped trying to sleep as recorded in sleep diary

    Time frame: Week 4, Week 12

  6. Change from baseline in subjective total sleep time (sTST) under the treatment of HS-10506

    sTST: the total sleep time reported by the participant in sleep diary

    Time frame: Baseline, Week 4, Week 12

  7. Incidence and severity of adverse events (AE)

    An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 4 months

  8. Incidence and severity of serious adverse events (SAE)

    An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participants and/or may require medical or surgical intervention to prevent one of the outcomes listed above

    Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 4 months

  9. Withdrawal symptoms by Physician Withdrawal Checklist (PWC-20)

    PWC-20 is a 20-item questionnaire and the score of each item ranges from 0-3 (0=not present, 1=mild, 2=moderate, 3=severe) with higher scores indicating greater severity of withdrawal symptoms

    Time frame: The day after the last administration and at least 3 days after discontinuation of the medication

  10. Rebound insomnia by sleep diary during the follow-up period

    Rebound insomnia is defined as worsened sleep relative to baseline after study drug treatment was completed, rebound insomnia is assessed using the data collected in sleep diary, including estimated minutes from the time that the participant attempted to sleep until sleep onset as recorded in sleep diary (subjective sleep onset latency, sSOL), estimated minutes of wake at night from initial sleep onset to the time when the participant stopped trying to sleep as recorded in sleep diary (subjective wake after sleep onset, sWASO) and the total sleep time reported by the participant in sleep diary ( subjective total sleep time, sTST)

    Time frame: Baseline, Follow-up Period (3-6 days)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jun 2028, 24 months later.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 24 months is above that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 14, 2026
StartEst.
May 29, 2026
Primary completionEst.
Jun 28, 2028
CompletionEst.
Aug 12, 2028
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07587385
Responsible party
Sponsor
First posted
May 14, 2026
Start date
May 29, 2026 (estimated)
Primary completion
Jun 28, 2028 (estimated)
Completion
Aug 12, 2028 (estimated)
Last update
May 14, 2026

Study contacts

Huan Yu Yu Principal Investigator
Contact
dr.yuhuan@163.com
021-54602182
Yuping Wang Wang Principal Investigator
Contact
wangyuping01@sina.cn
13501186298

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10506

Start the discussion